<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40864459</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2380-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>JAMA cardiology</Title><ISOAbbreviation>JAMA Cardiol</ISOAbbreviation></Journal><ArticleTitle>Survival After Initial Stress Testing vs Anatomic Testing in Suspected Coronary Artery Disease: Long-Term Follow-Up of the PROMISE Randomized Clinical Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e252882</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamacardio.2025.2882</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Symptoms suggestive of coronary artery disease (CAD) often require noninvasive testing for diagnostic and prognostic evaluation.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To determine long-term outcomes in patients randomized to functional (stress) vs anatomic (coronary computed tomographic angiography [CTA]) initial testing.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This study is a 2025 follow-up analysis of mortality of participants in the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) randomized clinical trial, which was conducted from 2009 to 2014, using a 2024 National Death Index search. Median (IQR) follow-up duration was 10.6 (9.9-11.3) years; maximum follow-up was 12.4 years. PROMISE was conducted at 193 multispecialty outpatient sites in North America among 10&#x202f;003 symptomatic patients requiring testing for suspected CAD. Data analysis was conducted from August 2024 to March 2025.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="UNASSIGNED">Participants were randomized 1:1 to initial CTA or stress testing. Testing and subsequent care were performed by sites according to usual practices.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The PROMISE trial's original primary end point was death, myocardial infarction, unstable angina hospitalization, or major procedural complication. The primary end point for extended follow-up was all-cause death, with cardiovascular (CV) death as a secondary end point.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">At enrollment, mean (SD) participant age was 61 (8) years, 5270 participants (52.7%) were women, and 8762 (87.6%) had chest pain or dyspnea. Death occurred in 1128 participants (14.4%), including 558 (14.3%) in the CTA arm and 570 (14.5%) in the stress arm (unadjusted hazard ratio [HR], 0.98; 95% CI, 0.87-1.10). There was no demonstrable difference in cardiovascular mortality, although the point estimate favored CTA (HR, 0.84; 95% CI, 0.67-1.05; adjusted HR, 0.89; 95% CI, 0.41-1.94). There were no significant interactions between all-cause death or CV death and study arm by age (&lt;60 or &#x2265;60 years) (P value for interaction&#x2009;=&#x2009;.19), gender (P value for interaction&#x2009;=&#x2009;.60), or race and ethnicity (P value for interaction&#x2009;=&#x2009;.47). A CTA indicating any degree of abnormality, including mild (nonobstructive CAD), moderate, and severe findings, conferred elevated adjusted HRs of death (1.99-3.44; all P&#x2009;&lt;&#x2009;.001) compared to normal study results. Among stress testing results, only a severe abnormality was prognostically significant (HR, 1.45; 95% CI, 1.10-1.91). In landmark analyses of those alive at 90 days, there were no interactions between randomized testing and use of statins (P value for interaction&#x2009;=&#x2009;.22), &#x3b2;-blockers (P value for interaction&#x2009;=&#x2009;.76), or antiplatelet agents (P value for interaction&#x2009;=&#x2009;.49).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">In long-term follow-up of the PROMISE randomized clinical trial, initial noninvasive test selection in patients with stable symptoms of suspected CAD did not affect all-cause or CV mortality at 10 years.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">ClinicalTrials.gov Identifier: NCT01174550.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Douglas</LastName><ForeName>Pamela S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stebbins</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foldyna</LastName><ForeName>Borek</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Manesh R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mark</LastName><ForeName>Daniel B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Cardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Udo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Cleerly Inc, Denver, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Svati H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhanti</LastName><ForeName>Brooke</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagidipati</LastName><ForeName>Neha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01174550</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Cardiol</MedlineTA><NlmUniqueID>101676033</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Patel reported grants from Bayer, Indorsia, the Patient-Centered Outcomes Research Institute, Regeneron, and the US National Heart, Lung, and Blood Institute and serving as a consultant or on an advisory board for Bayer, Janssen, Medscape, Novartis, and Regeneron outside the submitted work. Dr Lu reported grants from the American Heart Association, AstraZeneca, Ionis Pharmaceuticals, Johnson &amp; Johnson Innovation, Kowa Pharmaceuticals America, MedImmune, the National Academy of Medicine, the National Institutes of Health (NIH), and the Risk Management Foundation of the Harvard Medical Institutions and personal fees from Eli Lilly outside the submitted work. Dr Hoffmann reported being an employee of Cleerly outside the submitted work. Dr Shah reported grants from AstraZeneca, nference, the NIH, Owkin, and Verily outside the submitted work. Dr Pagidipati reported grants from Alnylam, Amgen, Bayer, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, and Novo Nordisk; personal fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Corcept, Corsera, Eli Lilly, Esperion, Merck, New Amsterdam, Novartis, and Novo Nordisk; and serving on data safety monitoring boards for Johnson &amp; Johnson and Novartis outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>29</Day><Hour>8</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>29</Day><Hour>8</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>27</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40864459</ArticleId><ArticleId IdType="pmc">PMC12392145</ArticleId><ArticleId IdType="doi">10.1001/jamacardio.2025.2882</ArticleId><ArticleId IdType="pii">2838118</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144(22):e368-e454. doi: 10.1161/CIR.0000000000001029</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001029</ArticleId><ArticleId IdType="pubmed">34709879</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrints C, Andreotti F, Koskinas KC, et al. ; ESC Scientific Document Group . 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae177</ArticleId><ArticleId IdType="pubmed">39210710</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas PS, Hoffmann U, Patel MR, et al. ; PROMISE Investigators . Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372(14):1291-1300. doi: 10.1056/NEJMoa1415516</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1415516</ArticleId><ArticleId IdType="pmc">PMC4473773</ArticleId><ArticleId IdType="pubmed">25773919</ArticleId></ArticleIdList></Reference><Reference><Citation>Newby DE, Adamson PD, Berry C, et al. ; SCOT-HEART Investigators . Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018;379(10):924-933. doi: 10.1056/NEJMoa1805971</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1805971</ArticleId><ArticleId IdType="pubmed">30145934</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams MC, Wereski R, Tuck C, et al. ; SCOT-HEART Investigators . Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland. Lancet. 2025;405(10475):329-337. doi: 10.1016/S0140-6736(24)02679-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)02679-5</ArticleId><ArticleId IdType="pubmed">39863372</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladapo JA, Hoffmann U, Lee KL, et al. Changes in medical therapy and lifestyle after anatomical or functional testing for coronary artery disease. J Am Heart Assoc. 2016;5(10):e003807. doi: 10.1161/JAHA.116.003807</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.116.003807</ArticleId><ArticleId IdType="pmc">PMC5121482</ArticleId><ArticleId IdType="pubmed">27733347</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas PS, Hoffmann U, Lee KL, et al. ; PROMISE investigators . PROspective Multicenter Imaging Study for Evaluation of chest pain: rationale and design of the PROMISE trial. Am Heart J. 2014;167(6):796-803.e1. doi: 10.1016/j.ahj.2014.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2014.03.003</ArticleId><ArticleId IdType="pmc">PMC4044617</ArticleId><ArticleId IdType="pubmed">24890527</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann U, Ferencik M, Udelson JE, et al. ; PROMISE investigators . Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation. 2017;135(24):2320-2332. doi: 10.1161/CIRCULATIONAHA.116.024360</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.116.024360</ArticleId><ArticleId IdType="pmc">PMC5946057</ArticleId><ArticleId IdType="pubmed">28389572</ArticleId></ArticleIdList></Reference><Reference><Citation>Mini&#xf1;o AM, Klein RJ. Mortality from major cardiovascular diseases: United States, 2007. US Centers for Disease Control and Prevention . Accessed March 15, 2025. https://www.cdc.gov/nchs/data/hestat/cardio2007/cardio2007.pdf</Citation></Reference><Reference><Citation>Adamson PD, Newby DE. The SCOT-HEART trial. what we observed and what we learned. J Cardiovasc Comput Tomogr. 2019;13(3):54-58. doi: 10.1016/j.jcct.2019.01.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcct.2019.01.006</ArticleId><ArticleId IdType="pmc">PMC6669238</ArticleId><ArticleId IdType="pubmed">30638705</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>